CD49f Is an Efficient Marker of Monolayer- and Spheroid Colony-Forming Cells of the Benign and Malignant Human Prostate

Hidekazu Yamamoto1, John R. Masters1, Prokar Dasgupta2,3, Ashish Chandra4, Rick Popert2, Alex Freeman5, Aamir Ahmed1*

1 Prostate Cancer Research Center, Division of Surgery and Interventional Science, University College London, London, United Kingdom, 2 Department of Urology, Guy’s and St. Thomas’ NHS Foundation Trust, Great Maze Pond, London, United Kingdom, 3 MRC Centre for Transplantation, King’s Health Partners, Guy’s Hospital, London, United Kingdom, 4 Department of Histopathology, Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom, 5 Department of Histopathology, University College London Hospital, London, United Kingdom

Abstract

Stem cells may play a role in the development and maintenance of proliferative diseases of the prostate such as prostate cancer and benign prostatic hyperplasia. Cell membrane protein markers, CD49f, CD133 and CD44, have been shown to identify putative prostate stem cells, but a lack of consensus exists with regards to the most efficient marker(s) for stem-like cell identification. This study aimed to determine whether previously reported markers had equal capacity to select monolayer and spheroid colony-forming cells (CFCs), which were used as surrogate readouts of stem-like cells, and to characterize the expression of CD49f, CD44 and CD133 by flow cytometry and immunohistochemistry. In benign prostate cells, CD49f+, CD44+, and CD133+ cells represented 5.6 ± 3.1%, 28.2 ± 4.1% and 0.10 ± 0.06% of total cells. Both monolayer- and spheroid-CFCs existed at a frequency of approximately 0.5% of total cells. CD49f+, CD44+, and CD133+ subpopulations differed significantly in their ability to select benign CFCs. The highest recovery of CFCs was achieved by CD49f+ selection (98%), whereas CD44+ or CD133+ selection led to poor CFC-recovery (17% and 3%, respectively). For the first time, we show highly efficient recovery of CFCs from advanced prostate cancer by CD49f+, but not by CD44+ or CD133+ selection. Furthermore, CD133 expression (AC133 clone) could not be detected in benign prostate cells by either immunohistochemistry or flow cytometry. We conclude that CD49f, but not previously described stem cell markers CD133 and CD44, to be optimal for selection of monolayer- and spheroid-CFCs in the benign and malignant prostate.

Introduction

Dysfunctional prostate stem cells are thought to drive the development and progression of proliferative diseases of the prostate such as prostate cancer and benign prostatic hyperplasia [1–3]. The paradigm states that specific eradication of abnormal stem cells could lead to better treatment of these conditions [2], and methods to deliver targeted therapies against specific subpopulations of cells already exist [4].

Targeting abnormal stem cells however requires knowledge of specific marker proteins expressed in the subpopulation. Previous investigations have identified a number of putative markers of prostate stem cells [5–7], including CD49f [5], CD44 [6], and CD133 [7], alpha2 integrin [6], and Trop2 [5], although currently there is no consensus on the optimal marker(s) for stem cell identification. Similar markers (CD44, CD133 [8] and CD49f [9]) could also identify stem-like cells in prostate cancer. The current literature also lacks evaluation of markers in advanced prostate cancer, a condition associated with a poor prognosis [10]. It is not known whether marker(s) of prostate stem-like cells in benign tissue differ to those in aggressive cancer tissue.

The aims of this study were to characterize the expression of CD49f, CD44 and CD133 in freshly-isolated cells, and compare the efficiency of each candidate marker to identify monolayer and spheroid colony-forming cells (CFCs). CFCs have been used as in vitro surrogates of stem-like cells in benign [5,11,12] and malignant prostate cells [8,9]. Both monolayer-CFCs [11,13,14] and spheroid- CFCs [5,15] demonstrate many of the properties of stem cells such as self-renewal, proliferation, three-dimensional gland-formation, and multipotency [11,13,16,17]. In contrast to in vivo tissue regeneration assays, colony-forming assays allow enumeration of CFCs within a cell population by colony counts [5,11,13,18]. Here, fresh prostate tissue was enzymatically dissociated into a single cell suspension and labelled with antibody for immunomagnetic cell separation. Subsequently, monolayer- and spheroid-colony-formation assays were used for measurement of CFC yields in fractionated cells. For the first time, we evaluate putative stem cell markers in tissues obtained from patients with at
least locally-advanced prostate cancer. Our results indicate significant differences in the capacity of each marker to identify CFCs; and we demonstrate that selection for CD49f+ cells has the highest efficiency of CFC isolation in both the benign and malignant prostate.

**Results**

Flow cytometric characterization of CD49f+, CD44+ and CD133+ subpopulations in cells isolated from benign human prostate tissue

Flow cytometry was used to determine the proportions of benign prostate cells expressing CD49f, CD44 (clone G44–26) and CD133 (clone AC133). Scatter gating and propidium iodide was used to exclude debris and dead cells arising from tissue digestion (Figure 1A). The specificities of each antibody were validated by positive and negative controls (Figure S1). CD49f+, CD44+, and CD133+ cells represented 5.6±3.1% (n = 5), 28.2±4.1% (n = 3) and 0.1±0.06% (n = 5) of total cells, respectively. Although CD133+ cells could be detected, cellular proportions were not significantly different to that of the isotype control samples (n = 3, p = 0.74) (Figure 1B).

Monolayer and spheroid CFCs of the benign human prostate

Prostate stem cells, in the mouse, are capable of generating both monolayer- and spheroid-colonies in vitro [11]. To demonstrate the colony forming ability of human prostate cells, freshly-isolated human prostate cells were seeded, in parallel, in monolayer- and spheroid-colony-formation assays as previously described [11,19]. Representative images for each assay are shown (Figure 2A, B). Colony forming efficiencies (CFE, see methods) for monolayer- and spheroid-colony-formation rates were significantly lower (13.9±17.9% and 3.1±1.9%, respectively, Figure 3A). Therefore, the monolayer CFC-yield following CD49f+ selection was 7-fold and 33-fold lower than CD44+ or CD133+ selection, respectively (Figure 3B). Results were similar for spheroid CFC-recovery, demonstrating the highest spheroid CFC-recovery in the CD49f+ fraction (98.9±1.1%), whereas CD44+ or CD133+ cells recovered 5.7±2.1% and 0.7±0.6%, of total CFCs, respectively (Figure 3C).

The AC133 epitope is undetectable by immunohistochemistry

The results described above indicated that AC133 clone-selected CD133+ cells lacked statistically significant colony-forming capacity (Figure 3). To further assess the protein expression of CD133, immunohistochemistry was conducted using frozen prostate sections and two CD133 antibody clones, AC133, and C24B89. Antibody specificities were validated using known positive controls (Caco-2 and HT29 cell lines) [21], which confirmed punctuate, apically polarised expression of CD133 (Figure 4A, B), as described previously [21]. Surprisingly, no immunohistochemical evidence of CD133 expression was found for either clone in 100 slides of hemi-prostate sections (Figure 4C).

To further characterize the CD133+ population, we determined its expression relative to CD49f, a marker that we found to be most selective for CFCs. Dual-label analysis conducted by flow cytometry showed CD133+ cells and CD49f+ cells to be independent cell populations (n = 3) (Figure 4D).

Further characterization of CD49f+ cells of the benign human prostate

Expression of CD49f (clone GoH3) was observed in the cell membranes of basal cells lining the prostatic acini (Figure 5A). CD49f co-localized with CK5 (Figure 5B), and expression polarised towards the outer surface of basal cells facing the stroma, as previously reported [22] (Figure 5A).

CD49f expression was also found in endothelial cells, as demonstrated by co-localization with CD31 (Figure 5C (i–iv)), a pan-endothelial marker [23,24]. CD49f+/CD31+ cells were arranged either in a luminal (Figure 5C (i,iii) or linear configuration (Figure 5C (ii,iv)), consistent with the normal histological arrangement of endothelial cells (as assessed by a histopathologist). Moreover, CD31+ cells were exclusive within CD49f+ cells, accounting for 3.2±1.5% of total human prostate cells (n = 3) (Figure 5D). CD31 expression, however, did not identify CFCs as shown by the lack of clonogenic capacity of CD31+ cells in contrast to CD31− cells (n = 3) (Figure 5E). 45.3±5.2% of CD49f+ cells did not express the androgen receptor (AR) [25], and very few were positive for prostate specific antigen (PSA), a marker of luminal cell marker [26]. These results, in combination, indicated that CFCs are likely to be CD49f+/CD31−, basal-like cells, with and without AR expression.
Figure 1. Flow cytometric live-cell analysis of freshly-isolated prostate cells for the identification of CD49f+, CD133+ and CD44+ subpopulations. [A] Sequential gating is used to exclude debris by positive selection of scatter gate R1, select single cells by positive selection of pulse width gate R2, and exclude dead cells by negative selection of propidium iodide-positive gate R3. [B] Representative dot plots of prostate cells labelled with each antibody. Scatter profiles of prostate cells expressing CD49f, CD44 or CD133 are also shown on the right. FS = Forward scatter, SS = Side scatter.

doi:10.1371/journal.pone.0046979.g001
Selection of CFCs within locally advanced prostate biopsy tissue

Eight core needle biopsy samples (clinico-pathological characteristics of the five patients are shown in Table 1) were obtained from patients with locally advanced or metastatic prostate cancer, of which five samples survived the combination of cell isolation, MACS, and monolayer colony formation. Tissue was digested using collagenase to give a single cell suspension (in a manner similar to that described for benign tissue, above) and MACS was used to obtain positive and negative fractions using antibodies for CD49f, CD44, and CD133. A representative colony formation assay is shown (Figure 6A). The numbers of colonies arising from each fraction were counted to determine the CFC-recovery (Figure 6). CFC-recovery was highest for CD49f (90.6±3.7%) compared to CD44 (18.3±12.5) or CD133 (2.2±2.5) (Figure 6B), similar to the data obtained from benign prostate cells.

Discussion

A direct in vitro comparison of cell surface markers, CD49f, CD44, and CD133, showed CD49f to select CFCs with the highest efficiency in both benign and malignant prostate cells. CD49f expression also identifies the cell of origin of prostate cancer [27,28], and the tumor-initiating subpopulation in a prostate cancer model [9]. Our results indicate that CD49f expression identifies CFCs within high-risk prostate cancer.

CFCs have been used as an in vitro surrogate readout of stem-like cells in a number of adult tissues [11,13,29–31]. For the prostate, this is supported by the equivalence of markers that identify CFCs and tissue regenerating stem cells [5,32]. Bonafide prostate stem cell markers remain controversial, however, as genetic lineage tracing experiments have shown that stem cell subpopulations could be defined by other markers [33].

Here, we demonstrate that monolayer- and spheroid-CFCs were rare, both present at a frequency of approximately 0.5% of total prostate cells (Figures 2A, B). CFCs underwent clonal proliferation, generated branching ductal structures (Figure 2B) and expressed both basal and luminal lineage markers (Fig. 2D). CD49f is an integrin, a receptor with a high binding affinity for collagen as used in our monolayer colony forming assays. An interaction between CD49f and collagen was theoretically possible, however, the lack of collagen coating of culture flasks did not affect the overall result that CD49f optimally selected for CFCs (Figure S5).

Our findings are consistent with previous studies that indicate CD49f as a marker of epithelial stem cells [5,11,13,28]. A striking finding in our study, however, was that the vast majority of CFCs (90–98%) resided within the CD49f+ population, not only in benign but also malignant prostate tissue. This implies that targeting of CD49f+ cells in the malignant prostate would eliminate the vast majority of the clonogenic cell population.

Further characterization also revealed CD49f+ cells to be comprised of two cell types, CK5+ basal epithelial cells, and...
CD31+ endothelial cells (Figures 5C,D). The fact endothelial cells expressed CD49f is pertinent in the context of cancer treatment, as neovascularization is a critical hallmark of cancer [34]. Targeting CD49f+ cells in prostate cancer could therefore simultaneously eliminate clonogenic cells and abnormal endothelial cells associated with neovascularisation.

We found a lack of AR expression in a subpopulation of CD49f+ cells (Figure 5F), consistent with a study that showed AR

Figure 3. Comparison of markers for selection of monolayer- and spheroid-CFCs. [A] Following MACS, total monolayer-colonies arising from each (+)ve and (−)ve fraction were counted to determine the monolayer CFC-recovery, i.e. proportion of input CFCs which are fractionated to the (+)ve fraction (n = 3). The CD49f+ fraction contained 97.9±0.3% of monolayer-CFCs, in contrast to CD44+ and CD133+ cell fractions which contained 13.9±17.9% and 3.1±1.9%, respectively. [B] A typical monolayer CFC-assay is shown. (+)ve and (−)ve fractions were derived from immunomagnetic sorting of 50,000 cells, each plated onto 10 cm culture dishes. [C] Following MACS, total spheroid-colonies arising from each (+)ve and (−)ve cell fractions were counted to determine the spheroid CFC-recovery (n = 3). The CD49f+ fraction contained 98.9±1.1% of spheroid CFCs, in contrast to CD44+ and CD133+ cell fractions which contained 5.7±2.1% and 0.7±0.6%, respectively (p<0.001). [D] CD49f+ were 10.6 fold more enriched in CFCs compared to unsorted cells, and significantly more enriched in CFCs compared to CD49f− cells (p<0.05) (n = 6). No significant CFC enrichment was detected upon comparison of CD44+ and CD44− cells (n = 5), or between CD133+ and CD133− cells (n = 3), respectively. ** p<0.05, * p>0.05.

doi:10.1371/journal.pone.0046979.g003
expression in a subset of basal epithelial cells [25]. The lack of AR expression is considered a feature of androgen-independence of prostate stem cells [35]. Similar findings are reported in prostate cancer, where stem-like cells with efficient tumor-initiation capacity were found within a subpopulation of the AR−/PSA− cells in CWR22 orthotopic xenografts [36]. The lack of PSA expression as a marker is also reported in a study that showed PSA−/lo cells, in contrast to PSA+ cells, to possess higher tumorigenicity and sphere-colony forming capacity in androgen-ablated mice [37].

CD133 is a well-characterized marker for hematopoietic [38] and neural stem cells [39], although controversy exists regarding its utility in other tissues [40]. A previous study showed selection for CD133+ cells resulted in enrichment for monolayer-CFCs, although several pre-selection steps were required immediately prior to CD133+ selection, including differential centrifugation, “basal-like” cell selection, and rapid attachment selection [7]. Another marker, CD44, has been suggested as marker for stem-like cells [41], although until now, direct comparisons of CFC numbers within CD133+ or CD44+ cells, against respective CD133− or CD44− cells, have not been performed. We show that CD44+ and CD133+ cells were depleted in CFCs compared to their respective negative populations, in both benign (Figure 3) and malignant prostate cells (Figure 6). These results imply that a single therapeutic agent targeting CD44+ or CD133+ cells in prostate cancer would not target the majority of clonogenic cells.

Our study also demonstrates an approach to compare different sorted subpopulations in parallel, with incorporation of validation assays for quality control. To minimize false positive signals at flow cytometry, we used live cell analysis in conjunction with dead cell exclusion [42] (Figure 1A). The specificities of antibodies were
Figure 5. Characterization of CD49+ cells in the benign prostate. A. CD49 expression was assessed in frozen sections of prostate tissue at low (i), medium (ii) and high magnification (iii, iv) by confocal microscopy. Expression was polarised towards the outer surface of the basal cell layer as reported previously (iii, iv) [22]. B. Co-expression of CD49 with CK5, a basal cell specific marker. C. CD49 expression was also found in endothelial cells as demonstrated by co-expression with CD31, a pan-endothelial cell marker. Endothelial cells formed either a luminal (rows (i) & (ii)), or a linear structure (rows (iii) & (iv)) within the stroma. Co-localization of CD31 with CD49 (indicated by yellow color) was only observed in the stromal compartment but not in the basal layer. D. Human prostate cells labeled with CD31 and CD49 (representative of 3 samples). CD31+ cells alone represented in 3.0±1.5% of human prostate cells. CD31+ cells formed a distinct subpopulation within CD49+ cells, and all CD31+ cells were CD49+. 
confirmed using well-characterized positive and negative controls to control for non-specific binding (Figure S1). Accuracy of MACS was validated by cell yield and purity analysis (Figures S2, S3, S4). Finally, we also avoided pre-selection steps to ensure that cells were sorted purely according to the expression of a single marker.

We found CD133 to be a poor marker of CFCs using the stem cell-selective antibody clone AC133 [38]. AC133 selected the least number of CFCs in both benign and malignant cases (Figure 3, 6), and AC133 expression was not observed by immunohistochemistry in our frozen sections. Because glycosylation of epitopes may influence the detection of CD133 (AC133) expression [43], immunohistochemistry was also conducted using another commercially available clone C24B9 whose binding is not affected by glycosylation; however, this also failed to detect CD133 expression in prostate tissue sections. By flow cytometry, we found CD133+ cells alone to represent a rare population of around 0.1% within human prostate cells (Figure 1B), similar to previous reports [7], although this percentage was statistically no different to isotype cells. Data for isotype controls were not shown in previous studies of flow cytometric expression analysis of fresh prostate cells [7,43]. Variability in CD133 expression, however, is well-recognized in other tissues [40,44], and reports of CD133 expression in the prostate also vary widely from that of no expression [45], to abundant expression in luminal cells [46]. Our results of immunohistochemistry and flow cytometry support findings by Sotomayer et al. [45], which showed AC133 epitope expression to be either too rare to be detected or not present in the prostate.

Conclusions

We have characterized the expression of putative stem cell markers, CD49f, CD44, and CD133, in benign and malignant prostate cells. Functional assays demonstrate CD49f to be the most efficient marker for identifying the colony-forming cell population within benign prostatic hyperplasia and advanced prostate cancer tissues.

Materials and Methods

Ethics statement

Ethical approval was given by the Joint UCL/UCLH committee on the ethics of human research. The review board approved the use of human tissue for prostate cancer research, in compliance with the International Committee on Harmonisation of Good Clinical Practice (ICH GCP).

Patient consent and tissue collection

Informed written consent was given by each patient prior to prostate tissue acquisition. Benign prostate tissue was obtained from 27 patients undergoing holmium laser enucleation of prostate (HoLEP), to obtain tissue pieces around 1–2 mm in diameter. All HoLEP samples were confirmed as histologically benign by the uropathologist. Clinical characteristics of each patient are shown in Table S1.

Biopsy tissues from clinically locally-advanced prostate cancer were obtained from 8 patients with PSA more than 50 ng/ml, undergoing diagnostic transrectal ultrasound-guided prostate biopsies. An 18-gauge biopsy needle was used to take two core biopsies from each patient, in addition to standard diagnostic biopsies (6–12 cores). Adjacent diagnostic biopsies were sent separately for histopathological correlation. The average wet weight of each biopsy was 0.5±1.23 mg.

Preparation of a single cell suspension of human prostate cells

The tissue was washed, minced and digested at 37°C in PrEGM solution (Lonza), containing 600 U/ml collagenase IV, 0.4% bovine serum albumin and 100 U DNase I, for up to 4 h (2 h for biopsy tissue) and filtered through 100 µm and then 40 µm meshes to obtain a single cell suspension. Pharmlyse [BD Biosciences] was added to lyse red cells and remaining cells were counted using trypan blue exclusion. The average viable cell yield from HoLEP tissue was 4.4±3.7±10^6 cells/prep (range: 0.4–14.1±10^6 cells, n = 27). For biopsy tissue, two cores from each patient were pooled prior to mechanical and enzymatic digestion, yielding approximately 50,000–80000 cells per patient.

Flow cytometric analysis

The following antibodies were used for flow cytometric analysis: CD49f (clone GoH3, BD Biosciences), CD44 (clone G44-26, BD Biosciences), and CD133 (clone AC133, Miltenyi Biotec), and CD31 (clone WM59, BD Biosciences). Freshly-isolated cells were incubated with fluorochrome-labelled antibody or isotype control.

E. Colony-forming cell assays conducted using CD31+ and CD31− populations conducted by sorting 50,000 cells by MACS (n = 3) showed, in all assays, almost no colonies in the CD31+ fraction. Scale bar = µm. F. A representative flow cytometric co-expression analysis of CD49f with androgen receptor (AR) or PSA is shown.

doii:10.1371/journal.pone.0046979.g005

Figure 6. CFC-recovery following CD49f+, CD44+, and CD133+ selection, in advanced prostate cancer. [A] A representative monolayer colony-formation assay arising from positive and negative fractions of positive markers is shown. Amongst the positively selected fractions, the greatest numbers of colonies is found in the CD49f− fraction. [B] CD49f+ selection recovers the largest number of monolayer-CFCs.

doii:10.1371/journal.pone.0046979.g006
antibody in PBS containing 1% BSA, and analysed using the CyAn™ ADP Analyser (Beckman Coulter). Isotype control antibodies were used to set the positive gates. Forward and side scatter gates, and pulse width selection, were used to exclude small debris, and aggregated cells, respectively (Figure 1A). Propidium iodide was used for dead cell exclusion (Figure 1A) [13]. Multicolor compensation was conducted post-analysis using median intensity values of the control population. 50,000 to 100,000 live, single cell events were recorded per analysis. Bi-exponential scales and isodensity contour lines were used to display dot plots [47].

**Monolayer colony-formation assay**

Cells were plated onto dishes pre-coated with 10 μg/ml rat-tail collagen I (Sigma-Aldrich) in serum-free Prostate Epithelial Cell Growth Medium (PrEGM) containing penicillin (10 U/ml) and streptomycin (10 μg/ml) [19]. NIH/3T3 cells, treated with Mitomycin C (10 μg/ml), were plated at 15000 cells per cm² to act as a feeder layer. A colony was defined as a cluster of more than 32 cells at day 12 [19].

**Spheroid colony-formation assay**

Cells were suspended in a 1:1 mixture of PrEGM:Matrigel, and then plated around the rims of wells of a 6 or 24 well plate [11]. PrEGM was added after allowing each gel to solidify for 15 min. A spheroid colony was defined as a sphere-shaped three-dimensional colony of at least 50 μm in diameter at 12 days. For enzymatic dissociation of sphere colonies into single cells, Matrigel scaffolds were liquefied using dispase to release the spheroid colonies. Spheroid colonies were collected and pelleted in centrifuge tubes and dissociated using collagenase and trypsin, as described previously [11].

**Immunohistochemistry**

Frozen tissue sections were used for immunohistochemical analysis. A cryostat was used to obtain 4–8 μm sections measuring approximately 2×2 cm from frozen tissue blocks freshly cut at cystoprostatectomy. Tissues were all confirmed retrospectively as histologically benign. Each frozen section was fixed for 60 s in 70% ethanol, washed three times in PBS, and incubated with 5% BSA for 45 min at RT (room temperature) to block non-specific binding. The following unlabelled primary antibodies were purchased; CD49f (clone GoH3, BD Biosciences), CD31 (clone WM59, BD Biosciences), CD133 (clone AC133, Miltenyi Biotec), CD133 (clone C24B9, Cell Signalling Technology), and used with Alexa-Fluor-conjugated secondary antibodies (Invitrogen). Briefly, samples were incubated overnight at 4°C with primary antibodies, and for 60 min at RT in the dark with secondary antibody. Images were taken using the TCS SPE2 confocal microscope (Leica Microsystems).

**Cell separation**

Immunomagnetic cell separation (MACS) was conducted following the manufacturer’s protocol (Miltenyi Biotec). Briefly, prostate cells were labeled with fluorochrome-conjugated antibodies, washed, and incubated with anti-fluorochrome magnetic nanobeads. Samples were passed through a magnetized MACS MS column to collect the negative fraction. The column was then demagnetized and flushed twice to collect the positive fraction. For determination of post-MACS cell yields, 1×10⁶ cells were sorted in triplicate and viable cell yields were measured by trypan blue exclusion.
CFC-recovery and Colony-forming efficiency (CFE)

CFC-recovery was defined as: (total colonies arising from the positive fraction)/total colonies arising from both positive and negative fractions) [46]. To measure CFC-recovery, 50,000 human prostate cells were immunomagnetically sorted based on expression of one marker, and each positive and negative fraction was seeded onto individual 10 cm dishes for monolayer colonies, or in Matrigel® to generate spheroid colonies. Colonies were counted on day 12.

CFE was defined as: (colonies per dish)/(cells seeded per dish). Relative CFE, defined as (CFE of sorted cell fraction)/CFE of unsorted cells, was used to standardize CFE across samples.

Data analysis and statistics

Unless otherwise stated, data is presented as mean ± s.d. Statistical analyses were performed using the Graphpad Prism software.

Supporting Information

Figure S1 Evaluation of specificity of CD49f (GoH3), CD44 (G44-26) and CD133 (AC133) antibodies using cell lines. Dead cells and cell doublets were excluded as described in the methods section. Specificities of all three antibodies were confirmed as consistent with previous studies; CD49f was highly expressed in >90% of PC3, LNCaP and DU145 cells [49]; CD44 showed expression in >98% of PC3 cells, <1% of LNCaP, and in a subpopulation of DU145 cells, as previously reported [41,49–51]. CD133 was expressed in >98% of Caco-2 and HT29 cells [21,43,52,53].

Figure S2 Post-MACS cell yields of (+)ve and (−)ve fractions are expressed as a percentage of pre-MACS input cells (n = 3). Positive controls (PC3 for CD49f and CD44, Caco-2 for CD133) were used to evaluate the technical success of immunomagnetic cell separation.

Figure S3 Flow cytometric purity assessment of positive and negative cell fractions following immunomagnetic separation of freshly-isolated human prostate cells using CD49f and CD44 antibodies (n = 3 patient samples, R1, R3, and R20, see Table S1).

Gates were set using isotype controls of unsorted cells. Purities of the CD49f+ and CD49f− fractions were 91.5±6.6% and 91.1±6.3%, respectively. Purities of the CD44+ and CD44− fractions were 91.5±5.6% and 88.2±2.9%, respectively.

References

1. Lawson DA, Witte ON (2007) Stem cells in prostate cancer initiation and progression. J Clin Invest 117: 2044–2050.
2. Rey T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105–111.
3. Isaac JT (2008) Prostate stem cells and benign prostate hyperplasia. Prostate 68: 1025–1034.
4. Perez EA, Ronsisvalle EL, Summ VJ, Jeong JH, Davidson NE, et al. (2011) Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31. Journal of Clinical Oncology 29: 3366–3373.
5. Goldberg D, Movassaghi T, Gibbons RA, Nakazawa K, et al. (2003) Trop-2 is an integrin with unique expression and functional characteristics in prostate cancer cells. Cancer Res 63: 4625–4632.
6. Gates AR, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946–10953.
7. Collin AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prognostic importance of the CD49f+ tumor-initiating cell population in human prostate cancer. Cancer Res 65: 10946–10953.
8. Mulholland DJ, Xin L, Morim A, Lawson D, Witte O, et al. (2009) Lin-Sca-1+CD49fhigh stem/progenitor cells are tumour-initiating cells in the Pten-null prostate cancer model. Cancer Res 69: 8553–8562.
9. Kroft LR, Teng E, Sinclair AJ, Picard K, et al. (2007) CD49f high stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res 69: 8553–8562.
10. Hadashik BA, Gleave ME (2007) Therapeutic options for hormone-refractory prostate cancer in 2007. Urologic Oncology-Seminars and Original Investigations 25: 413–419.
11. Lawson DA, Xin L, Lukacs RU, Cheng D, Witte ON (2007) Isolation and functional characterization of murine prostate stem cells. Proc Natl Acad Sci U S A 104: 181–186.
12. Xin L, Lukacs RU, Lawson DA, Cheng D, Witte ON (2007) Self-renewal and multilineage differentiation in vitro from murine prostate stem cells. Stem Cells 25: 2760–2769.
13. Eirew P, Stingl J, Raouf A, Turashvili G, Aparicio S, et al. (2008) A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability. Nat Med 14: 1383–1389.
14. Xin L, Lawson DA, Witte ON (2005) The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci U S A 102: 6942–6947.
15. Reynolds BA, Rietze RL (2005) Neural stem cells and neuropeptides: re-evaluating the relationship. Nat Methods 2: 333–336.
16. Ema H, Suda T, Miura Y, Nakauchi H (1990) Colony formation of clone-sorted human hematopoietic progenitors. Blood 75: 1941–1946.
17. Reynolds BA, Weiss S (1992) Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 255: 1707–1710.
18. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, et al. (2006) Purification and unique properties of mammary epithelial stem cells. Nature 439: 993–997.
19. Hudson DL, O’Hare M, Watt FM, Masters JR (2000) Proiferative heterogeneity in the human prostate: evidence for epithelial stem cells. Lab Invest 80: 1243–1250.
20. Uzagre AR, Xu Y, Isaacs JT (2004) In vitro cultivating and characteristics of transplant amplifying epithelial cells from human prostate tissue. J Cell Biochem 91: 196–205.
21. Cordeil D, Roper K, Hellwig A, Tavian M, Miraglia S, et al. (2000) The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 275: 5512–5520.
22. Knox JD, Cress AE, Clark V, Manriquez L, Affinito KS, et al. (1994) Differential Expression of Extracellular-Matrix Molecules and the Alpha(6)-Integrins in the Normal and Neoplastic Prostate. Am J Pathol 145: 167–174.
23. Hewett PW, Murray JC (1995) Human Microvessel Endothelial-Cells - Isolation, Culture and Characterization. In Vitro Cell Dev Biol Anim 29A: 823–830.
24. van Beijnum JR, Rousch M, Castermans K, van der Linden E, Griffioen AW (2000) Isolation of endothelial cells from fresh tissues. Nat Protoc 3: 1085–1091.
25. Boonhoff H, Remmerberg K (1993) Widespread Distribution of Nuclear Androgen Receptors in the Basal-Cell Layer of the Normal and Hyperplastic Human Prostate. Virchows Archiv A-Pathological Anatomy and Histopathology 422: 35–38.
26. Hudson DL, Goy AT, Fry P, O’Hare MJ, Watt FM, et al. (2001) Epithelial cell differentiation pathways in the human prostate: identification of intermediate phenotypes by keratin expression. J Histochem Cytochem 49: 271–278.
27. Lavoix DA, Zong Y, Memarzadeh S, Xin L, Huang J, et al. (2010) Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci U S A 107: 2610–2615.
28. Goldstein AS, Huang J, Guo C, Garryaw IP, Witte ON (2010) Identification of a cell of origin for human prostate cancer. Science 329: 568–571.
29. Sato T, Yores RG, Snippert HJ, van de WM, Barker N, et al. (2009) Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459: 262–265.
30. Dorrell C, Erker L, Schug J, Kopp JL, Canaday PS, et al. (2011) Prospective isolation of a bipotential clonogenic liver progenitor cell in adult mice. Genes Dev 25: 1193–1203.
31. Rietje RL, Valacsin H, Brooker GF, Thomas T, Voss AK, et al. (2001) Purification of a pluripotent neural stem cell from the adult mouse brain. Nature 412: 736–739.
32. Garryaw IP, Sun W, Tran CP, Perner S, Zhang B, et al. (2009) Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459: 262–265.
33. Dolan C, Erker L, Schug J, Kopp JL, Canaday PS, et al. (2011) Prospective isolation of a bipotential clonogenic liver progenitor cell in adult mice. Genes Dev 25: 1193–1203.
34. Rietje RL, Valacsin H, Brooker GF, Thomas T, Voss AK, et al. (2001) Purification of a pluripotent neural stem cell from the adult mouse brain. Nature 412: 736–739.
35. Garryaw IP, Sun W, Tran CP, Perner S, Zhang B, et al. (2010) Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of prostate regeneration in vivo. Prostate 70: 491–501.
36. Wang X, Kruthoff-de Juho M, Economides KD, Walker D, Yu H, et al. (2009) A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461: 495–500.
37. Hanahan D, Weinberg RA (2011) Hallmarks of Cancer: The Next Generation. Cell 144: 646–674.
38. Hudson DL, Goy AT, Fry P, O’Hare MJ, Watt FM, et al. (2001) Epithelial cell differentiation pathways in the human prostate: identification of intermediate phenotypes by keratin expression. J Histochem Cytochem 49: 271–278.
39. Rajasekhar VK, Studer L, Gerald W, Socci ND, Scher HI (2011) Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-kappaB phenotypes by keratin expression. J Histochem Cytochem 49: 271–278.
40. Liu AY (1994) Expression of CD44 in prostate cancer cells. Cancer Lett 76: 63–68.
41. Liu AY (2000) Differential expression of cell surface molecules in prostate cancer cells. Cancer Res 60: 3429–3434.
42. Liu AY (1994) Expression of CD44 in prostate cancer cells. Cancer Lett 76: 63–68.
43. Liu AY (2000) Differential expression of cell surface molecules in prostate cancer cells. Cancer Res 60: 3429–3434.
44. Liu AY (1994) Expression of CD44 in prostate cancer cells. Cancer Lett 76: 63–68.
45. Liu AY (2000) Differential expression of cell surface molecules in prostate cancer cells. Cancer Res 60: 3429–3434.
46. Liu AY (1994) Expression of CD44 in prostate cancer cells. Cancer Lett 76: 63–68.
47. Liu AY (2000) Differential expression of cell surface molecules in prostate cancer cells. Cancer Res 60: 3429–3434.
48. Liu AY (1994) Expression of CD44 in prostate cancer cells. Cancer Lett 76: 63–68.
49. Liu AY (2000) Differential expression of cell surface molecules in prostate cancer cells. Cancer Res 60: 3429–3434.
50. Liu AY (1994) Expression of CD44 in prostate cancer cells. Cancer Lett 76: 63–68.
51. Liu AY (2000) Differential expression of cell surface molecules in prostate cancer cells. Cancer Res 60: 3429–3434.
52. Liu AY (1994) Expression of CD44 in prostate cancer cells. Cancer Lett 76: 63–68.
53. Liu AY (2000) Differential expression of cell surface molecules in prostate cancer cells. Cancer Res 60: 3429–3434.
54. Liu AY (1994) Expression of CD44 in prostate cancer cells. Cancer Lett 76: 63–68.
55. Liu AY (2000) Differential expression of cell surface molecules in prostate cancer cells. Cancer Res 60: 3429–3434.
56. Liu AY (1994) Expression of CD44 in prostate cancer cells. Cancer Lett 76: 63–68.
57. Liu AY (2000) Differential expression of cell surface molecules in prostate cancer cells. Cancer Res 60: 3429–3434.
58. Liu AY (1994) Expression of CD44 in prostate cancer cells. Cancer Lett 76: 63–68.